ABBOTT LABORATORIES
ABTNYSETrading Snapshot
- Day Range
- $101.54 β $103.93
- 52-Week Range
- $81.97 β $132.03
- Volume (shares)
- 5,464,176
- Avg Volume (shares)
- β
- Shares Outstanding
- 1.73B
- Next Earnings
- 2027-01-28
Fundamentals Snapshot
- Annual Revenue
- $44.33B
- Last Q Revenue
- $13.01B
- P/E Ratio
- 38.6
- P/S Ratio
- 3.8x
- EPS (TTM)
- $2.70
- Dividend Yield
- 2.35%
- Dilution (1yr)
- +0.1%
ABBOTT LABORATORIES
ABTAbout ABBOTT LABORATORIES
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

U.S. politician makes super suspicious Big Tech stock trades
Republican Rep. Pete Sessions of Texas has disclosed substantial stock sales involving major technology companies.

Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
Medtronic's 49-year dividend streak sounds impressive until you meet the two medical device rivals that have been raising payouts even longer, and the differences in yield, valuation, and balance sheet strength could res

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) ana

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Abbott: Demand Headwinds And Litigation Risks Priced-In - Spin-Off Tailwinds Ahead
FQ4'26 noise from EP/CGM demand headwinds has contributed to Abbott's lowered FY2026 guidance and range-bound stock price action afterwards. Nutrition spin-off may unlock MedTech/Diagnostic/Pharmaceutical's growth, impro

Abbott Laboratories $ABT Shares Purchased by Evergreen Capital Management LLC
Evergreen Capital Management LLC boosted its stake in shares of Abbott Laboratories (NYSE: ABT) by 40.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange C